AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 181 min read$SKYE

Schwab Andrew J. sold $65K of SKYE (indirect holdings)

Schwab Andrew J. sold 33,892 indirectly-held shares of Skye Bioscience, Inc. (SKYE) at $1.91 across 2 trades on 2026-09-16.

Original reporting
SEC EDGAR · Schwab Andrew J.
Published Sep 18, 2026, 10:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 10:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SKYE
Neutral
medium confidence
Mentioned
$SKYE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SKYENeutralLow
01

Why it matters

The disclosed sale is a primary source of information but its modest size limits actionable insight.

02

Market read

The filing provides a factual update on insider holdings with limited market impact.

03

What to watch

Potential upcoming clinical trial results or regulatory events not disclosed in the filing.

Relevance 3/10Novelty 4/10Timing: post‑filing

Background

Form 4 filings disclose insider trades and are required to be filed within two business days of the transaction.

Company-level read

Ticker impact

$SKYENeutralMedium confidence
Context

Director Andrew J. Schwab sold 33,892 shares of Skye Bioscience for $64,734 via a Form 4 filing.

Expected impact

Minimal impact; price likely unchanged.

Evidence & confidence

The transaction is a primary disclosure but the amount ($65K) is small for a public company, limiting trading relevance.

Market effects

Sector

None; the sale is company‑specific and does not affect the broader biotech sector.

Regional

None; the filing is a routine insider transaction.

Global

None; no broader market effect.

Counterpoint

What could challenge this read

If the insider is reducing exposure ahead of upcoming negative news, the stock could face downside pressure.

Key entities

  • Company
    Skye Bioscience, Inc.

    Biotech firm listed on Nasdaq under ticker SKYE.

  • Insider
    Andrew J. Schwab

    Director and 10% owner of Skye Bioscience.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SKYE insider trading history →

Related articles

AUG 17
$SKYEMedAI 8/10

Skye To Acquire Redx; $125M Financing Secures Path To RXC008 Phase 2 Trial; Stock Up

Skye Bioscience (SKYE) will acquire Redx Pharma via a scheme of arrangement, creating Nasdaq-listed Fibrx Therapeutics led by Redx management. The lead asset is RXC008 for fibrostenotic Crohn’s, with FDA Fast Track and Phase 2 topline data expected in H2 2028. Financing totals $125M, including a $68M PIPE and $36M Series A, funding operations into 2029. SKYE closed at $0.50.

rttnews.com4 min
AUG 14
$SKYEHighAI 9/10

Skye Bioscience, Inc.: Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

Skye Bioscience (Nasdaq: SKYE) will acquire privately held Redx Pharma via a UK scheme of arrangement, forming Fibrx Therapeutics that will trade on Nasdaq. The deal includes about $125 million in committed financings, including a ~$68 million PIPE and a $36 million Series A. Funds are expected to support RXC008 Phase 2 through 2029, with topline data in H2 2028.

finanznachrichten.de4 min
OCT 23
$RENTMed

Nexus Capital Management LP (Cohen Michael S, Flesh Daniel E.) purchased $2.2M of RENT (indirect holdings)

Nexus Capital Management LP purchased 632,922 indirectly-held shares of Rent the Runway, Inc. (RENT) at $3.55 ($2.25M total) on 2026-10-21. Filed jointly with Gateway Runway, LLC (Director), Gateway Runway Intermediate Holdings, Inc. (Director), NEXUS SPECIAL SITUATIONS III, L.P. (Director), NEXUS SPECIAL SITUATIONS III (CAYMAN), L.P. (Director), Nexus Special Situations GP III, LP (Director), Nexus Partners III, LLC (Director), Cohen Michael S (Director), Flesh Daniel E. (Director) and Giangiacomo Damian (Director).

SEC EDGAR1 min